Proportion of Prescribed Conditions & Latest Patient Approval Numbers To date, the TGA has approved SAS applications including, but not limited to, the following indications: chemotherapy-induced nausea and vomiting refractory paediatric epilepsy palliative care indications cancer pain neuropathic pain spasticity from neurological conditions anorexia and wasting associated with chronic illness (such as cancer) A break […]
Read More
UK CBD Sales Surge Research from two industry pressure groups reveals the UK cannabinoid (CBD) industry was worth £690mln in the 12 months to the end of April – up almost a third since a 2019 estimate. CBD is the non-psychoactive element derived from both marijuana and hemp plants. It is used in an […]
Read More
Medical Cannabis: where are we at? This is a fantastic article by respected experts Associate Professor Vicki Kotsirilos AM was Australia’s first authorised GP prescriber of medicinal cannabis in May 2018. Professor Iain S McGregor is the Academic Director of the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney’s Brain and Mind Centre. […]
Read More
Self-Identified Medical Cannabis Consumers Report Substituting It for Prescription Drugs Key Findings • 22% of respondents reported that medical cannabis has decreased pain (517 respondents, N=2,302).a • 39% reported that medical cannabis has improved quality of life (900 respondents, N=2,302). • 61% reported having replaced prescription opioids and benzodiazepines with medical cannabis (988 respondents, N=1,622). […]
Read More
Global pharma company Jazz Pharmaceuticals has reached an agreement to buy United Kingdom-based GW Pharmaceuticals, one of the largest medical cannabinoid businesses in the world, for $7.2 billion in cash and stock, the drugmakers announced Wednesday. The proposed transaction would be the largest move to date by a pharma company into cannabis, demonstrating that pharmaceutical […]
Read More